tjpls
Tropical Journal of Pharmaceutical and Life Sciences
Trop. j. pharm. life sci.
Jadoun Science Publishing Group India
IN
https://jadounscience.com
2349-9818
325
Research Article
Polymer Selection Governs Nanocarrier Performance in Nose-to-Brain Delivery: A Unified Box–Behnken Comparison of Chitosan, Polycaprolactone and PLGA Systems for Two Antidepressants
Anshuman Mohanty
rakeshjat75@yahoo.co.in
JJTU Research Scholar
Rakesh Kumar Jat
rakeshjat75@yahoo.co.in
Dibya Lochan Mohanty
rakeshjat75@yahoo.co.in
Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
Department of Pharmaceutics, School of Pharmacy, Anurag University, Hyderabad, Telangana, India
13
10
2026
Received: 13102026
Copyright (c) 2026
2026
<a rel="license" href="https://creativecommons.org/licenses/by-nc/4.0/"><img alt="Creative Commons License" src="//i.creativecommons.org/l/by-nc/4.0/88x31.png" /></a><p>This work is licensed under a <a rel="license" href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial 4.0 International License</a>.</p>
Nose-to-brain delivery
Box–Behnken design
Quality by Design
Chitosan; Polycaprolactone
PLGA; Viloxazine
Venlafaxine
In-situ gel
Nasal mucosa
[
[1] World Health Organization. Depressive disorder (depression). Fact sheet. Geneva: WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/depression
]
[
[2] Yang X, Fang Y, Chen H, et al. Temporal and spatial trend analysis of all-cause depression burden based on Global Burden of Disease (GBD) 2019 study. Sci Rep. 2024;14:12346. doi:10.1038/s41598-024-62381-9
]
[
[3] Singh D, Saadabadi A. Venlafaxine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Bookshelf ID: NBK535363
]
[
[4] Scherf-Clavel M, Weber H, Deckert J, et al. Joint population pharmacokinetic modelling of venlafaxine and O-desmethylvenlafaxine in healthy volunteers and patients to evaluate the impact of morbidity and concomitant medication. Br J Clin Pharmacol. 2022. PMCID: PMC9772442
]
[
[5] Frampton JE. Viloxazine extended-release: a review in attention-deficit/hyperactivity disorder in adults. CNS Drugs. 2025. doi:10.1007/s40263-025-01227-y
]
[
[6] Yu C, Garcia-Olivares J, Candler S, et al. Viloxazine increases extracellular concentrations of norepinephrine, dopamine, and serotonin in the rat prefrontal cortex. J Exp Pharmacol. 2024;16:1–12. doi:10.2147/JEP.S433524
]
[
[7] Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–1972. doi:10.1038/jcbfm.2012.126
]
[
[8] Xu J, Tao J, Wang J, et al. Nose-to-brain drug delivery: from bench to bedside. Transl Neurodegener. 2025;14:12. doi:10.1186/s40035-025-00481-w
]
[
[9] Xu Y, Zhang C, Zhu X, et al. The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles: evidence from aggregation-caused quenching probes. Mol Pharm. 2019;16(4):1663–1673. PMID: 30841963
]
[
[10] Ge Y, Chen L, Liu S, et al. Advances in nasal drug delivery systems for central nervous system disorders. Pharmaceutics. 2024;16(7):929. doi:10.3390/pharmaceutics16070929
]
[
[11] Agosti E, Zeppieri M, Antonietti S, et al. Navigating the nose-to-brain route: a systematic review on lipid-based nanocarriers for central nervous system disorders. Pharmaceutics. 2024;16(3):329. doi:10.3390/pharmaceutics16030329
]
[
[12] Rodrigues S, Costa AMR, Grenha A, et al. Recent advances on chitosan-based nanoparticles for brain drug delivery. Polymers. 2025;17(22):3055. doi:10.3390/polym17223055
]
[
[13] Sharma D, Sharma S, Kumar A. Chitosan nanoparticles for intranasal drug delivery. Pharmaceutics. 2024;16(6):746. doi:10.3390/pharmaceutics16060746
]
[
[14] Esquivel R, Juárez J, Almada M, et al. Synthesis and characterization of new thiolated chitosan nanoparticles obtained by ionic gelation method. Int J Polym Sci. 2015;2015:502058. doi:10.1155/2015/502058
]
[
[15] Bonaccorso A, Pellitteri R, Ruozi B, et al. Synthesis and characterization of PCL-idebenone nanoparticles for potential nose-to-brain delivery. Pharmaceutics. 2023. PMCID: PMC10216815
]
[
[16] Sun H, Mei L, Song C, et al. Polycaprolactone microspheres and their biodegradation. Polym Degrad Stab. 1999;66(1):85–94. doi:10.1016/S0141-3910(99)00145-7
]
[
[17] Rosch JG, Winter H, DuRoss AN, et al. Role of the lactide:glycolide ratio in PLGA nanoparticle stability and release under lysosomal conditions. Pharmaceutics. 2023. PMCID: PMC10531859
]
[
[18] Rassu G, Sorrenti M, Catenacci L, et al. In vitro comparative study of solid lipid and PLGA nanoparticles designed to facilitate nose-to-brain delivery of insulin. Int J Mol Sci. 2021;22(24):13258. doi:10.3390/ijms222413258
]
[
[19] Tzeyung AS, Md S, Bhattamisra SK, et al. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: in vitro and ex vivo evaluation of efficacy and safety. Int J Pharm. 2020;588:119731. PMID: 32818538
]
[
[20] Rassu G, Gavini E, Giunchedi P, et al. Nose to brain delivery of insulin loaded in PLGA and chitosan-coated PLGA nanoparticles: a promising approach for Alzheimer's disease therapy. J Drug Deliv Sci Technol. 2025;107:106710. Reference requires DOI verification.
]
[
[21] Fonseca-Gomes J, Loureiro JA, Tanqueiro SR, et al. A reevaluation of chitosan-decorated nanoparticles to cross the blood-brain barrier. Membranes. 2020;10(9):212. PMCID: PMC7559907
]
[
[22] Mohanty A, Danodia A, Mohanty D. Formulation, evaluation, and optimization of viloxazine-loaded chitosan nanoparticles in in-situ gel for nose-to-brain delivery in the effective management of depression. Int J Pharm Health Care Res. 2025;13(1):1–4. doi:10.61096/ijphr.v13.iss1.2025.1-4
]
[
[23] Müller RH, Jäcobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3–19. doi:10.1016/S0169-409X(00)00118-6
]
[
[24] Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57. doi:10.3390/pharmaceutics10020057
]
[
[25] Cavallaro G, Craparo EF, Sardo C, et al. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. Eur J Pharm Sci. 2012;47(5):855–861. Reference requires DOI verification.
]
[
[26] Rana R, Kumar A, Bhatt PC, et al. Development of escitalopram-loaded chitosan nanoparticle in-situ gel for nose-to-brain delivery. Front Pharmacol. 2025;16:1577331. doi:10.3389/fphar.2025.1577331
]
[
[27] Kellner M, Schmidt J, Hoffmann M, et al. Variability of nasal mucosa thickness and reliability of integrity markers in ex vivo permeation models. PMID: 40573284
]
[
[28] Raj R, Wairkar S, Sridhar V, et al. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2018;109:27–35. doi:10.1016/j.ijbiomac.2017.12.056
]
[
[29] Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Control Release. 2014;190:189–200. doi:10.1016/j.jconrel.2014.05.003
]
[
[30] Jain SA, Chauk DS, Mahajan HS, et al. Formulation and evaluation of nasal mucoadhesive microspheres of sumatriptan succinate. J Microencapsul. 2009;26(8):711–721. Reference requires DOI verification.
]
[
[31] Cho HJ, Balakrishnan P, Park EK, et al. Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride. Molecules. 2015;20(3):4124–4139. doi:10.3390/molecules20034124
]
[
[32] Shelke S, Shahi S, Jalalpure S, et al. Poloxamer 407-based intranasal thermoreversible gel of mometasone furoate. Drug Deliv. 2017;24(1):289–297. PMID: 28281209
]
[
[33] Zaki NM, Awad GA, Mortada ND, et al. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32(4–5):296–307. doi:10.1016/j.ejps.2007.08.006
]
[
[34] Basu S, Maity S. Preparation and characterisation of mucoadhesive nasal gel of azithromycin prepared with poloxamer and carbopol. PMID: 20500130
]
[
[35] Kaur P, Garg T, Rath G, et al. Development, optimization and evaluation of thermosensitive mucoadhesive in situ gel by Box-Behnken design. PMCID: PMC9102451
]
[
[36] Pandey V, Kohli S. Rheological characterization of poloxamer-based nasal in situ gels and spray pattern evaluation. Gels. 2025;11(10):841. doi:10.3390/gels11100841
]
[
[37] Cai Z, Song X, Sun F, et al. Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin. AAPS PharmSciTech. 2011;12(4):1102–1109. doi:10.1208/s12249-011-9678-y
]
[
[38] Naik A, Nair H. Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin. Biomed Res Int. 2014;2014:847547. PMCID: PMC4086251
]
[
[39] Vieira ACC, Chaves LL, Pinheiro S, et al. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis. Int J Pharm. 2018;536(1):478–485. doi:10.1016/j.ijpharm.2017.11.071
]
[
[40] Bruinsmann FA, Pigana S, Aguirre T, et al. Chitosan-coated nanoparticles: effect of chitosan molecular weight on nasal transmucosal delivery. Pharmaceutics. 2019;11(2):86. doi:10.3390/pharmaceutics11020086
]
[
[41] Alvarez-Trabado J, Diebold Y, Sanchez A. Designing lipid nanoparticles for topical ocular drug delivery. Int J Pharm. 2017;532(1):204–217. doi:10.1016/j.ijpharm.2017.09.017
]
[
[42] Costa C, Moreira JN, Amaral MH, et al. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release. 2019;295:187–200. doi:10.1016/j.jconrel.2018.12.049
]
[
[43] Harugade A, Sherje AP, Pethe A. Chitosan: a review on properties, biological activities and recent progress in biomedical applications. React Funct Polym. 2023;191:105634. doi:10.1016/j.reactfunctpolym.2023.105634
]
[
[44] Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023;53(1):119–152. doi:10.1007/s40005-022-00589-5
]
[
[45] Yadav S, Singh A, Palei NN, et al. Chitosan-based nanoformulations: preclinical investigations, theranostic advancements, and clinical trial prospects for targeting diverse pathologies. AAPS PharmSciTech. 2024;25(8):263. doi:10.1208/s12249-024-02986-5
]
[
[46] Costa CP, Moreira JN, Sousa Lobo JM, et al. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B. 2021;11(4):925–940. doi:10.1016/j.apsb.2021.02.012
]
[
[47] Ahmad E, Feng Y, Qi J, et al. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale. 2017;9(3):1174–1183. doi:10.1039/C6NR07581A
]
[
[48] Bors LA, Erdő F. Overcoming the blood-brain barrier: challenges and tricks for CNS drug delivery. Sci Pharm. 2019;87(1):6. doi:10.3390/scipharm87010006
]
[
[49] Erdő F, Bors LA, Farkas D, et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155–170. doi:10.1016/j.brainresbull.2018.10.009
]
[
[50] Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184–1189. doi:10.1016/S1359-6446(02)02529-1
]